Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Grand Pharmaceutical Group Limited ( (HK:0512) ) has shared an update.
Grand Pharmaceutical Group Limited has scheduled a board meeting for 26 March 2026 to review and approve the annual results of the company and its subsidiaries for the financial year ended 31 December 2025. The board will also consider the payment of a final dividend, signaling potential returns for shareholders and providing clarity on the group’s financial performance and capital allocation plans.
The announcement confirms the company’s corporate governance schedule and indicates that investors can expect detailed financial disclosures following the meeting. Any decision on a final dividend will be closely watched by stakeholders as an indicator of profitability, cash generation, and management’s outlook on the business.
The most recent analyst rating on (HK:0512) stock is a Buy with a HK$8.50 price target. To see the full list of analyst forecasts on Grand Pharmaceutical Group Limited stock, see the HK:0512 Stock Forecast page.
More about Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited is a Hong Kong-listed pharmaceutical company incorporated in Bermuda and engaged in the healthcare sector. The group operates through a board comprising four executive directors and four independent non-executive directors, overseeing its activities in the pharmaceutical industry and related markets.
Average Trading Volume: 4,815,353
Technical Sentiment Signal: Buy
Current Market Cap: HK$25.63B
See more insights into 0512 stock on TipRanks’ Stock Analysis page.